In this project, the research team exploits the experience in the field of liposomes acquired from previous FFC Ricerca funding (FFC#21/2019, FFC#14/2017, FFC#17/2013) to hind the effects of Mycobacterium abscessus (Mab) infection and improve the effectiveness of Kaftrio in the treatment of cystic fibrosis (CF). The project involves the enrolment of person with CF under Kaftrio therapy from which macrophages (cells involved in the immune response) will be isolated to evaluate the best formulation of liposomes loaded with the antibiotic amikacin capable of killing Mab. The research group proposes a combined approach directed both towards the host (person with CF) and towards the pathogenic bacterium, through in vitro, ex vivo and in vivo experiments. Experiments on macrophages will be carried out to identify the best therapeutic formulation of the liposome/Kaftrio/amikacin combination, the results of which will be validated in vivo on models of chronic Mab infection. This project could provide important information about a new therapeutic approach for better resolution of chronic lung infections in CF patients treated with Kaftrio, limiting the inflammatory response. The results could open up to a clinical trial of this combined therapeutic formulation.